Abcam Plc expect to report revenue growth of approximately 28%, or 30% for the sic months period ended December 31, 2012, on a constant currency basis, which, taking into account the unaudited revenues of Epitomics and Ascent for the same period last year, represents underlying growth at constant currency of just over 12%.
1st Jan change | Capi. | |
---|---|---|
+8.54% | 100B | |
+11.97% | 43.89B | |
-11.76% | 33.24B | |
+80.29% | 29.36B | |
-12.20% | 16.08B | |
+4.00% | 14.68B | |
-1.90% | 12.87B | |
+178.17% | 10.55B | |
+4.04% | 8.83B |